Data from the Prospective Lynch Syndrome Database indicated that MLH1 PGV carriers have a lifetime risk of PC estimated at 6.2%, with MSH2, EPCAM, MSH6, and PMS2 all having an estimated lifetime risk up to 1.6%, similar to the general population [19, 20]. Here, MSH2 is linked to pachyonychia congenita.